WHO Issues Warning Over Acute Shortage of Obesity Injections

Fewer than a tenth of patients eligible to benefit from weight-loss injections including Wegovy have access to them, caution the World Health Organization as it issues its inaugural advice on the drugs.

Given in excess of 1,000,000,000 people worldwide currently obese, it is urging increased and just access to this class of drugs.

Per estimates, over two billion could be living with obesity by 2030 unless action is taken.

"Our new guidelines acknowledges that excess weight is a chronic disease that can be managed with holistic and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and distribution challenges are key hurdles to broad access to the treatments that can help people shift substantial weight, says the organization.

Skinny Jab Scarcity

Despite the current most favorable outlook, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of eligible patients, according to the WHO.

The guideline urges governments and firms to widen access, by measures like licensing agreements.

The intellectual property rights on a key compound – the core component of the drug Wegovy – is scheduled to end in multiple nations in 2026.

How Weight-Loss Jabs Function

GLP-1 drugs replicate a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so individuals eat less.

Individuals typically see weight reduction within a few weeks of beginning the weekly injections.

Research points to people may regain a significant portion after a year of halting the drug, as their typical hunger come back.

Being carrying excess weight increases your risk for experiencing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies.

Excess weight impacts individuals in every country and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.